Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDGN's Cash to Debt is ranked higher than
90% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. MDGN: No Debt )
MDGN' s 10-Year Cash to Debt Range
Min: 0.24   Max: No Debt
Current: No Debt

Interest Coverage No Debt
MDGN's Interest Coverage is ranked higher than
59% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDGN: No Debt )
MDGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 23.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -115.58
MDGN's ROE (%) is ranked higher than
54% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. MDGN: -115.58 )
MDGN' s 10-Year ROE (%) Range
Min: -611.28   Max: -76.67
Current: -115.58

-611.28
-76.67
ROA (%) -94.93
MDGN's ROA (%) is ranked higher than
53% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. MDGN: -94.93 )
MDGN' s 10-Year ROA (%) Range
Min: -484.61   Max: -64.26
Current: -94.93

-484.61
-64.26
ROC (Joel Greenblatt) (%) -4488.13
MDGN's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. MDGN: -4488.13 )
MDGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5026.23   Max: -1228.57
Current: -4488.13

-5026.23
-1228.57
EBITDA Growth (3Y)(%) 1.80
MDGN's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. MDGN: 1.80 )
MDGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.5   Max: 184.4
Current: 1.8

-17.5
184.4
» MDGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MDGN Guru Trades in

Q2 2013

MDGN Guru Trades in Q2 2013

Jim Simons 15,300 sh (-41.83%)
» More
Q3 2013

MDGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2015

MDGN Guru Trades in Q1 2015

Jim Simons 25,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with MDGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.42
MDGN's P/B is ranked higher than
63% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. MDGN: 7.42 )
MDGN' s 10-Year P/B Range
Min: 0   Max: 30.2
Current: 7.42

0
30.2
EV-to-EBIT -7.08
MDGN's EV-to-EBIT is ranked lower than
51% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDGN: -7.08 )
MDGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.08

Current Ratio 18.08
MDGN's Current Ratio is ranked higher than
94% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. MDGN: 18.08 )
MDGN' s 10-Year Current Ratio Range
Min: 0.24   Max: 18.08
Current: 18.08

0.24
18.08
Quick Ratio 18.08
MDGN's Quick Ratio is ranked higher than
94% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MDGN: 18.08 )
MDGN' s 10-Year Quick Ratio Range
Min: 0.24   Max: 18.08
Current: 18.08

0.24
18.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.18
MDGN's Price/Net Cash is ranked higher than
82% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. MDGN: 8.18 )
MDGN' s 10-Year Price/Net Cash Range
Min: 2.86   Max: 148.8
Current: 8.18

2.86
148.8
Price/Net Current Asset Value 7.57
MDGN's Price/Net Current Asset Value is ranked higher than
81% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. MDGN: 7.57 )
MDGN' s 10-Year Price/Net Current Asset Value Range
Min: 2.66   Max: 74.4
Current: 7.57

2.66
74.4
Price/Tangible Book 7.42
MDGN's Price/Tangible Book is ranked higher than
67% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. MDGN: 7.42 )
MDGN' s 10-Year Price/Tangible Book Range
Min: 3.22   Max: 46.5
Current: 7.42

3.22
46.5
Earnings Yield (Greenblatt) -14.10
MDGN's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. MDGN: -14.10 )
MDGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -26.3   Max: 0
Current: -14.1

-26.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MEDU.UK, MEDG.UK,
Medgenics Inc was incorporated on January 27, 2000 in Delaware. The Company is a medical technology and therapeutics company. The Company along with its subsidiaries is engaged in the research and development of products in the field of biotechnology and associated medical equipment. The Company has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue. The Company has also developed an Interferon Alpha secreting Biopump for the treatment of viral Hepatitis. The Company's Biopump Platform Technology converts a small piece of the patient's own dermal skin tissue into a protein. Its proprietary device, the DermaVac, is used to extract a small piece of tissue via a form of needle biopsy from the skin's lower level - the dermis - of patient under local anesthesia. The Company is also developing TARFT platform designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. Its EPODURE Biopump is designed to provide a safer, more reliable, and more cost-effective anemia therapy. The Company faces competition within protein/peptide therapeutics, directly from established competitors using alternative protein manufacturing and delivery methods for EPO and in many orphan and rare disease areas respectively. The Company's production, distribution, and marketing of products employing its technology, and its development activities, are subject to various governmental regulations in the United States and in other countries. In the United States, its products are regulated as biologics and medical devices and are subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations of the FDA, as well as to other federal, state, and local statutes and regulations.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK